<DOC>
	<DOCNO>NCT00004172</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . Combining chemotherapy autologous peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . Radiation therapy use high-energy x-rays damage tumor cell . PURPOSE : Phase II trial compare effectiveness two regimen chemotherapy filgrastim plus stem cell transplantation treat patient previously untreated stage III stage IV breast cancer .</brief_summary>
	<brief_title>Chemotherapy , Filgrastim , Stem Cell Transplantation With Radiation Therapy Treating Patients With Stage III Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess antitumor response , survival , disease free survival follow high dose carboplatin , ifosfamide , thiotepa autologous peripheral blood stem cell ( PBSC ) support consolidation radiotherapy sit pretreatment bulk disease patient previously treat advanced breast cancer . II . Assess toxicity high dose chemotherapy patient . III . Compare effectiveness PBSC mobilization high dose cyclophosphamide filgrastim ( G-CSF ) vs G-CSF alone patient population . OUTLINE : Patients assign 1 2 peripheral blood stem cell ( PBSC ) mobilization group discretion attend physician : Group 1 : Patients receive high dose cyclophosphamide IV 6 hour filgrastim ( G-CSF ) subcutaneously ( SQ ) daily begin 24 hour completion cyclophosphamide continue 3 day blood count recover PBSC harvest . Group 2 : Patients receive G-CSF SQ daily alone PBSC harvest . Both group : PBSC harvest day 15-19 cyclophosphamide infusion blood count recover . Patients receive high dose carboplatin IV continuously , ifosfamide IV 4 hour , thiotepa IV 1 hour day -5 -3 . PBSC reinfused begin 48 hour completion combination chemotherapy . Patients receive G-CSF SQ begin day 0 continue 3 day blood count recover . Sites pretransplantation metastasis great 3 cm irradiate begin transplantation blood count recover . Patients follow every month 1 year . PROJECTED ACCRUAL : A total 12-24 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove previously treat stage III IV breast cancer No CNS disease Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Physiologic 65 Menopausal status : Not specify Performance status : ECOG 0 1 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Hepatic function normal unless due liver metastases Bilirubin le 1.5 time normal SGOT SGPT less 1.5 time normal Alkaline phosphatase less 1.5 time normal If hepatitis C antibody positive , liver function must normal OR liver dysfunction must due metastatic disease chronic hepatitis Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance great 50 mL/min Cardiovascular : LVEF normal No myocardial infarction within past 6 month No significant arrhythmia require medication No history congestive heart failure Pulmonary : DLCO least 50 % predict FEV1 and/or FVC least 75 % predict No serious nonneoplastic pulmonary disease ( severe chronic obstructive lung disease ) would preclude study therapy Other : Not pregnant Negative pregnancy test HIV negative Hepatitis B C surface antigen negative No active serious medical condition would preclude study therapy PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>